Corient Private Wealth
LGND icon

Corient Private Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

Corient Private Wealth’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.7M Buy
11,699
+5,349
+84% +$1.26M ﹤0.01% 1029
2026
Q1 		$1.27M Buy
6,350
+2,789
+78% +$552K ﹤0.01% 1508
2025
Q4 		$673K Buy
3,561
+741
+26% +$142K ﹤0.01% 1716
2025
Q3 		$500K Buy
+2,820
New +$419K ﹤0.01% 1791

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's LGND Position: Q2 2026 in Review

Corient Private Wealth increased its Ligand Pharmaceuticals (LGND) stake by 84% in Q2 2026, buying an estimated $1.26M and bringing the position to 11,699 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Corient Private Wealth first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Corient Private Wealth held 11,699 shares of Ligand Pharmaceuticals worth $3.7M as of Q2 2026.
  • Corient Private Wealth bought 5,349 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.26M.
  • Ligand Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1029 holding.
  • Corient Private Wealth first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.